These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. ACTH and cortisol plasma levels in cancer patients treated with medroxyprogesterone acetate at high dosages. Papaleo C; Carella C; Zito GA; Figlia A; Capuano F; Amato G Chemioterapia; 1984 Aug; 3(4):220-2. PubMed ID: 6099752 [TBL] [Abstract][Full Text] [Related]
7. Complete regression of skeletal metastases from hypernephroma after angioinfarction and medroxyprogesterone acetate therapy. Amin R Urology; 1988 Sep; 32(3):254-8. PubMed ID: 2970709 [No Abstract] [Full Text] [Related]
8. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer]. Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant medroxyprogesterone acetate and steroid hormone receptors in category M0 renal cell carcinoma. An interim report of a prospective randomized study. Pizzocaro G; Piva L; Salvioni R; Di Fronzo G; Ronchi E; Miodini P J Urol; 1986 Jan; 135(1):18-21. PubMed ID: 2934557 [TBL] [Abstract][Full Text] [Related]
11. Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma. Tomic R; Ljungberg B; Damber JE Scand J Urol Nephrol Suppl; 1988; 110():185-7. PubMed ID: 2973122 [No Abstract] [Full Text] [Related]
14. Trilostane-induced inhibition of cortisol secretion results in reduced negative feedback at the hypothalamic-pituitary axis. Teshima T; Hara Y; Takekoshi S; Nezu Y; Harada Y; Yogo T; Teramoto A; Osamura RY; Tagawa M Domest Anim Endocrinol; 2009 Jan; 36(1):32-44. PubMed ID: 19041802 [TBL] [Abstract][Full Text] [Related]
15. Postoperative prophylactic use of progesterone in renal cell carcinoma. Satomi Y; Takai S; Kondo I; Fukushima S; Furuhata A J Urol; 1982 Nov; 128(5):919-22. PubMed ID: 6217352 [TBL] [Abstract][Full Text] [Related]
16. Cushing syndrome as a presenting symptom of renal tumors in children. Segers H; van der Heyden JC; van den Akker EL; de Krijger RR; Zwaan CM; van den Heuvel-Eibrink MM Pediatr Blood Cancer; 2009 Aug; 53(2):211-3. PubMed ID: 19353619 [TBL] [Abstract][Full Text] [Related]
17. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer. Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689 [TBL] [Abstract][Full Text] [Related]
18. Effect of salt loading on proopiomelanocortin (POMC) messenger ribonucleic acid levels, POMC biosynthesis, and secretion of POMC products in the mouse pituitary gland. Elkabes S; Loh YP Endocrinology; 1988 Oct; 123(4):1754-60. PubMed ID: 2843347 [TBL] [Abstract][Full Text] [Related]
19. Medroxyprogesterone acetate lowers plasma corticotropin and cortisol but does not suppress anterior pituitary responsiveness to human corticotropin releasing factor. Lang I; Zielinski CC; Templ H; Spona J; Geyer G Cancer; 1990 Nov; 66(9):1949-53. PubMed ID: 2146010 [TBL] [Abstract][Full Text] [Related]
20. [Study of the in vitro effect of MPA on an established cell line from a human renal cell carcinoma]. Yamashita S Nihon Hinyokika Gakkai Zasshi; 1985 Jun; 76(6):822-30. PubMed ID: 2933544 [No Abstract] [Full Text] [Related] [Next] [New Search]